Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers

This publication has 15 references indexed in Scilit:

• Molecular and Genetic Aspects of Lung Cancer
  American Journal of Respiratory and Critical Care Medicine, 2000
• An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions
  Lung Cancer, 1999
• p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
  Oncogene, 1997
• Diagnostic and Prognostic Value of Cyfra 21-1 Compared with Other Tumour Markers in Patients with Non-small Cell Lung Cancer: A Prospective Study of 116 Patients
  European Journal Of Cancer, 1997
• The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy
  Immunology Today, 1996
• The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer
  Molecular Medicine Today, 1996
• Serum p53 antibodies as early markers of lung cancer
  Nature Medicine, 1995
• The Tissue Polypeptide Antigen Serum Test in the Preoperative Evaluation of Non-Small Cell Lung Cancer
  Chest, 1995
• Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
  Proceedings of the National Academy of Sciences, 1992
• Two dimensional benzyldimethyl-n-hexadecylammonium chloride → sodium dodecyl sulfate preparative polyacrylamide gel electrophoresis: A high capacity high resolution technique for the purification of proteins from complex mixtures
  Analytical Biochemistry, 1989